Phase 3
Completed N=80
Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia
Sarcopenia · Geriatric · Muscle Mass · Muscle Strength
Source: ClinicalTrials.gov NCT05869383 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: IGF-1 Levels — 78.92; 77.08 ng/dl
◆ Published Evidence
Emerging
3citations · ~2 / year
<i>Ophiocephalus striatus</i> Extract Supplementation Decreases Serum IL-6 Levels in Older People with Sarcopenia-A Single-Center Experience.
Summary
The goal of this Clinical Trial is to analyze effect of Ophiochepalus striatus extract on serum IGF-1 and IL-6 levels in elderly patients with sarcopenia. The main questions it aims to answer are:
1. Can giving Ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks increase IGF-1 levels in elderly people with sarcopenia?
2. Can administration of 2x5 grams dose of Ophiocephalus striatus extract for 2 weeks reduce IL-6 levels in elderly with sarcopenia?
3. Can the administration of Ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks reduce the SARC-F score in elderly people with sarcopenia?
4. Can the administration of Ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks increase muscle mass in elderly people with sarcopenia?
5. Can the administration of Ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks increase muscle strength in elderly people with sarcopenia?
6. Can administration of Ophiocephalus striatus extract at a dose of 2x5 grams for 2 weeks improve physical performance in elderly with sarcopenia?
Participants will:
1. Consume Ophiochepalus striatus extract 2x5 grams a day.
2. Checked blood before and after the intervention.
3. Measured muscle mass, muscle strength, and physical performance before and after the intervention.
Linked Publications
-
<i>Ophiocephalus striatus</i> Extract Supplementation Decreases Serum IL-6 Levels in Older People with Sarcopenia-A Single-Center Experience.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY IGF-1 Levels |
78.92; 77.08 | — |
| PRIMARY IL-6 Levels |
36.47; 44.51 | — |
Eligibility Criteria
Inclusion Criteria
- Elderly patients with sarcopenia diagnosed using AWGS criteria consist of low muscle mass: using the BIA examination tool where men: 3 times the upper limit of normal value
- Impaired kidney function with a glomerular filtration rate 10)
- History of hypersensitivity to Ophiocephalus striatus
- Refuse to participate in research
Data sourced from ClinicalTrials.gov (NCT05869383) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.